A low-cost benchtop oligonucleotide synthesizer using inkjet enzymatic DNA synthesis
Ended Project Grant Awarded Last action
- Award ID
- R01HG011736
- Recipient
-
DNA Script UEI KTGQARYH18T6
- Awarding agency
-
National Human Genome Research Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,776,703
Award facts
- Assistance listing
- 93.172 Human Genome Research
- Completion date
- Funding
-
- $10,302,375.14 Federal
- $1,474,328.00 Non-federal
- Place of performance
- France
Award details come from USAspending.gov.
Description
- Abstract
- The objective of this proposal is to develop a benchtop, inkjet-based, oligonucleotide synthesizer using aqueous, enzymatic DNA synthesis technologies for the parallel synthesis of up to 1 million high-quality oligonucleotides per day. The system will deliver >10-fold improvements in the key metrics of cost, quality, and throughput compared to existing technologies. The synthesis biochemistry will utilize engineered terminal deoxynucleotidyl transferase enzymes that have been optimized for incorporation of 3' aminoxy reversible terminator nucleotides. This approach has several advantages, including proven performance in the synthesis of oligonucleotides up to 300 nucleotides on microbeads. Here, we will adapt the technology to enable DNA synthesis on functionalized microscope slides using inkjets for precise reagent delivery. A multidisciplinary approach will be followed to advance toward the goals in terms of engineering for instrumentation development, biochemistry and protocol optimization, and performance benchmarking of the synthesized oligonucleotides. During the first year, we will build an initial testbed to enable verification and optimization of individual components, materials, reagents, and protocols. In the second year, we will build a fully automated prototype instrument, and refine the protocols and software to allow synthesis of long oligonucleotides. Finally, year-3, we will build multiple benchtop instruments and work with partner laboratories to test the oligonucleotides in several 'real world' applications. Subsequent commercialization of the instruments will democratize access to rapid high-density oligonucleotide synthesis, and revolutionize approaches to a wide variety of synthetic biology and functional genomics applications.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$1 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 |
Show 40 more
Latest 50 listed here. See the rest on GovTribe.
Quick answers
Who received award R01HG011736?
R01HG011736 was awarded to DNA Script by National Human Genome Research Institute (National Institutes of Health) on September 1, 2021.
How much is award R01HG011736 worth?
$11,776,703 has been obligated on R01HG011736: $10,302,375 in federal funding and $1,474,328 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award